MEET NINA

Your noninvasive
neuromodulation assistant

Drug-Free, Noninvasive, At-Home Therapy For OAB

For patients who don’t want to take another pill and aren’t ready for surgery, NiNA* may be an ideal alternative to medication. NiNA uses proprietary technologies to optimally target and activate the saphenous while maintaining user comfort. This simple, discreet system for the treatment of OAB requires just 30 minutes of stimulation and is designed to deliver significant, durable symptom reduction all done in the convenience of your own home.

85%

Physicians would prescribe NiNA to 85% of their OAB patients 1

3 to 1

patients prefer NiNA to medications 3 to 12

85%

Physicians would prescribe NiNA to 85% of their OAB patients 1

3 to 1

patients prefer NiNA to medications 3 to 12

Initial nSAFN clinical experience demonstrates efficacy on-par with published results for medications and other competing therapies

Noninvasive Saphenous Neuromodulation (nSAFN) has been studied in 3 feasibility studies to date at 7 centers in the US and Canada.3

78%

OAB responders3,4

65%

UUI responders3

85%

UUI reduction in UUI
responders3

28%

of patients were Dry3

NiNA vs Competitive Therapies

Medications

Significant side-effects

NO serious adverse effects 

Percutaneous Tibial Neuromodulation (PTNS)

Weekly office visits 

Done at home

Sacral Neuromodulation (SNS)

Surgery required

Completely noninvasive 

Botulinum Toxin

Bladder wall injections 

Completely noninvasive, done at home

the Future of NiNA

An Intelligent Companion App and Ecosystem

Not only does NiNA offer revolutionary at-home neuromodulation therapy, but the introduction of the NiNA CareTM app 6 will also add comprehensive educational content developed by world-renowned physicians– maximizing patient engagement and the potential for successful, durable outcomes.

1Primary market research study, conducted by third party Q2-2021, data on file.

2Primary market research study, conducted by third party Q1-2021, data on file.

3Feasibility clinical outcomes, data on file.

4Defined as >=50% reduction or return to normal voiding. UUI = urinary urge incontinence.

5Brazzelli, M., et al. (2006). Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. The Journal of Urology, 175(3 Pt 1), 835–841. 

6NiNA Care is currently in development and has not received market authorization for sale in the US, Canada, or any other geography.